All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
Obinutuzumab is a recombinant, humanized anti-CD20 monoclonal antibody.1 Treatment with obinutuzumab resulted in greater complete renal response at Week 52 (35% vs 23%; p = 0.115) and Week 104 (41% vs 23%; p = 0.026) in patients with lupus nephritis, versus placebo, meeting the primary endpoint of the phase II NOBILITY trial.1-3 No safety signals were reported.1
Below, we present a visual abstract summarizing a post-hoc analysis of the phase II NOBILITY trial on kidney outcomes with obinutuzumab, presented by Rovin et al.2 at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), and by Rovin et al.3 published in Arthritis Rheumatol. We also include a post-hoc analysis by Vital et al.3 on B-cell recovery with obinutuzumab, presented at the ACR Convergence 2023.
To download this visual abstract, click below.Download here
Biologics in the management of systemic lupus erythematosus: pooled efficacy and safety
Here, we summarize a systematic review and meta-analysis of clinical trials evaluating the efficacy and safety of biologics in the treatment of patients with...
ACR Convergence 2023 abstracts: What’s hot in systemic lupus erythematosus and lupus nephritis?
To help navigate the exciting content being presented at ACR Convergence 2023, we have provided recommendations for the top abstracts to look out for in...
Subscribe to get the best content related to lupus delivered to your inbox